Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Cabaletta Bio, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 109
- −11 vs. Q3 2024
- Shares held
- 38.4M
- −9.62M (−20.0%) vs. Q3 2024
- Total value
- $87.2M
- −$139.5M (−61.5%) vs. Q3 2024
- New holders
- 26
- 40 more added
- Sold out
- 37
- 25 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CABA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 139 | $490.4M |
| Q1 2026 | 108 | $227.5M |
| Q4 2025 | 95 | $166.9M |
| Q3 2025 | 75 | $162.0M |
| Q2 2025 | 86 | $110.7M |
| Q1 2025 | 93 | $50.3M |
| Q4 2024 | 109 | $87.2M |
| Q3 2024 | 120 | $226.7M |
| Q2 2024 | 142 | $380.0M |
| Q1 2024 | 159 | $870.9M |
| Q4 2023 | 128 | $1.10B |
| Q3 2023 | 97 | $622.6M |
| Q2 2023 | 84 | $470.5M |
| Q1 2023 | 72 | $203.9M |
| Q4 2022 | 61 | $183.9M |
| Q3 2022 | 54 | $7.76M |
| Q2 2022 | 55 | $17.8M |
| Q1 2022 | 62 | $36.9M |
| Q4 2021 | 66 | $68.9M |
| Q3 2021 | 61 | $211.3M |
| Q2 2021 | 63 | $135.5M |
| Q1 2021 | 68 | $180.1M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Cabaletta Bio, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 1,265,882 | $2.87M | 0.01% | +598,607+89.7% | Added |
| Morgan Stanley | 1,439,165 | $3.27M | 0.00% | +610,336+73.6% | Added |
| Fred Alger Management, LLC | 2,316,224 | $5.26M | 0.03% | −1,803,170−43.8% | Reduced |
| Jennison Associates LLC | 2,512,053 | $5.70M | 0.00% | −3,120,628−55.4% | Reduced |
| Bain Capital Life Sciences Investors, LLC | 2,760,888 | $6.27M | 0.74% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,867,722 | $6.51M | 0.00% | +314,012+12.3% | Added |
| BlackRock, Inc. | 3,397,260 | $7.71M | 0.00% | −1,396,224−29.1% | Reduced |
| Adage Capital Partners GP, L.L.C. | 3,634,473 | $8.25M | 0.01% | +597,828+19.7% | Added |
| T. Rowe Price Investment Management, Inc. | 4,074,006 | $9.25M | 0.01% | +400,282+10.9% | Added |
| VR Adviser, LLC | 0 | $0 | 0.00% | −1,563,952−100.0% | Sold out |
| Sofinnova Investments, Inc. | 0 | $0 | 0.00% | −1,533,883−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −1,278,444−100.0% | Sold out |
| Commodore Capital LP | 0 | $0 | 0.00% | −1,100,000−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −629,087−100.0% | Sold out |
| Redmile Group, LLC | 0 | $0 | 0.00% | −442,826−100.0% | Sold out |
| UBS Asset Management Americas Inc | 0 | $0 | 0.00% | −331,260−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −280,133−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −230,293−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −144,584−100.0% | Sold out |
| Crestline Management, LP | 0 | $0 | 0.00% | −143,575−100.0% | Sold out |
| Jump Financial, LLC | 0 | $0 | 0.00% | −109,786−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −98,673−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −87,455−100.0% | Sold out |
| Corton Capital Inc. | 0 | $0 | 0.00% | −66,741−100.0% | Sold out |
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −61,842−100.0% | Sold out |
| Ensign Peak Advisors, Inc | 0 | $0 | 0.00% | −36,873−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −33,251−100.0% | Sold out |
| MetLife Investment Management | 0 | $0 | 0.00% | −27,714−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −26,976−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −23,571−100.0% | Sold out |
| Keybank National Association | 0 | $0 | 0.00% | −21,506−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −12,229−100.0% | Sold out |
| Birchview Capital, LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −9,395−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −7,638−100.0% | Sold out |
| Virtus ETF Advisers LLC | 0 | $0 | 0.00% | −7,338−100.0% | Sold out |
| Point72 Asia (Singapore) Pte. Ltd. | 0 | $0 | 0.00% | −6,680−100.0% | Sold out |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −4,511−100.0% | Sold out |
| nVerses Capital, LLC | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Mirae Asset Global Investments Co., Ltd. | 0 | $0 | 0.00% | −1,767−100.0% | Sold out |
| Macroview Investment Management LLC | 0 | $0 | 0.00% | −1,131−100.0% | Sold out |
| Daiwa Securities Group Inc. | 0 | $0 | 0.00% | −175−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −191−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −93−100.0% | Sold out |
| Rothschild Investment LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |